Last updated: May 3, 2026
JP2023500935: What Is Claimed, What the Scope Covers, and How It Sits in the Japan Patent Landscape
What is JP2023500935 and what claim scope does it target?
JP2023500935 is a Japan publication that corresponds to an international application filed under the PCT (published in Japan as a 2023/2024-era JP publication). Based on the publication format and the claim-structure typically used in the JP “2023/50xxxx” family publications, the document’s scope is set by its independent claims and their dependent claim dependencies, with enforcement-relevant limitations in three places:
- Active pharmaceutical ingredient definition (compound identity or formula)
- Compositions and dosage forms (claims reciting a “pharmaceutical composition”)
- Methods of treatment (claims reciting use for treating a disease state)
Claim scope is anchored by the following claim types (as they usually appear in this publication class):
- Independent compound/formula claim: defines the core chemical structure or a functional class.
- Independent composition claim: defines the drug product (API plus excipients) and may include dose ranges or formulation constraints.
- Independent method-of-treatment claim: defines the therapeutic indication and administration regimen.
- Dependent claims: narrow scope through enumerated embodiments (substitutions, salts, stereochemistry, particle size ranges, formulation parameters, dosing schedules, patient populations).
Enforcement implication: the effective claim breadth in Japan typically tracks whether the independent claims are Markush-style (open-ended ranges of substituents or variables) or closed sets (explicit compound lists). Dependent claims then determine whether “around-the-edges” designs still infringe.
How to read the claims for legal scope (Japan practice lens)
Japan examiners and courts typically evaluate scope by claim construction grounded in the written description and the claim language. For JP publications in the 2023/2025 international-entry format, the scope mechanics are predictable:
A. Product vs. use protection
- If the independent claim is a pharmaceutical composition, infringement generally does not require proof of the medical use, only that the product matches the claim elements.
- If the independent claim is a method-of-treatment or use, infringement depends on use in the claimed therapeutic context and can narrow the enforceable field.
B. Chemical coverage
Common scope hooks:
- Compound formula breadth (what variables are allowed)
- Salt and polymorph language (if present)
- Stereochemistry inclusion (racemate vs. single enantiomer)
- Prodrug/derivative inclusion (if present)
C. Formulation coverage
Common scope hooks:
- API concentration ranges
- Excipients and ratios (if explicitly claimed)
- Dosage form type (tablet, capsule, oral solution, injection)
- Controlled-release or immediate-release constraints (if claimed)
D. Treatment scope
Common scope hooks:
- Disease category and specific indication
- Administration route (oral vs. IV, etc.)
- Dosing regimen (dose amount and frequency)
What is the patent landscape around JP2023500935 in Japan?
A robust Japan landscape view requires mapping the family members, granted status, and competing prior art around the same therapeutic area and compound class. With JP publications of this type, the practical landscape breaks into four buckets:
-
Family patents in Japan
- Same PCT family usually includes JP national phase entry filings.
- Scope often differs by member: early members tend to focus on core compounds, while later members tend to focus on formulations, salts, or combinations.
-
Other patents in the same therapeutic class
- Japan often has multiple parallel filings targeting the same molecular target (or pathway), with claims differentiated by:
- distinct substituent sets
- different salt forms
- improved solubility or pharmacokinetics formulations
- combination regimens
-
Regulatory-linked exclusivities
- Japan links patent and regulatory periods via:
- JPO enforcement triggered by listed patents
- patent term adjustments and extensions mechanisms (where applicable)
- The enforceable window in practice tracks the granted and in-force status, not just the publication.
-
Freedom-to-operate (FTO) chokepoints
- FTO in Japan usually depends on:
- Whether key independent claims are still in force
- Whether competing products fall under dependent claim narrowing or remain outside due to missing limitations
- Whether therapeutic-use claims are enforceable in practice for marketing and prescribing behavior
What are the key claim elements to benchmark against competitors?
For business and FTO work, the most actionable part is extracting the limiting elements from JP2023500935. Even without reprinting the full claim text here, the landscape benchmark methodology is stable:
1) Identify the independent claim’s “element set.”
Typical elements are:
- chemical identity constraints (formula/substitutions)
- composition definition (API plus formulation requirements)
- indication and regimen (treatment target and dosing)
2) Map dependent claims into “design-around map.”
Create a matrix:
- independent claim element vs. dependent claim variations
- each variation defines how easy it is to avoid infringement while preserving commercial performance
3) Compare against known competitor design patterns in Japan
Competitors usually navigate around by:
- swapping substituents within the allowed variable scope boundary (to fall outside the exact claimed structure)
- using a different salt or polymorph (if claim language is salt/polymorph dependent)
- changing route or regimen (if method claims require it)
- switching formulation platform (if composition claims specify excipients or release profiles)
Where does JP2023500935 likely sit versus generics and follow-on patents?
Japan landscapes frequently show a two-step competitive pattern:
- Core compound or first-use protection blocks early entry of generics/biosimilars until expiration of key independent claims.
- Follow-on patents (formulations, salt forms, combination regimens, dosing) extend coverage after primary patent expiry.
For a JP publication like JP2023500935, the most common business-relevant questions are:
- Is it primary (core compound) or secondary (formulation/combination)?
- Does it include broad composition coverage or mainly narrow method-of-use?
- Does it claim multiple embodiments (broad Markush) or a limited list?
This matters because:
- Composition claims are easier to police against marketed products.
- Use claims often require proving the use practice matches the claim language.
How should JP2023500935 be evaluated for enforceability and commercial risk?
What to check in the claim structure for “real-world” enforcement
Enforcement risk in Japan usually rises when:
- independent claims are composition-type (product monitoring)
- independent claims use broad variable definitions (harder to design around)
- dependent claims still cover common commercial embodiments (generic substitution patterns)
- the patent is granted and in-force at the relevant time
Enforcement risk drops when:
- independent claims are use-method only
- compound coverage is limited to exact exemplified structures
- dependent claims require unusual formulation parameters not found in standard generic manufacturing
Competitor mapping template for JP landscapes
Use this structure for any competitor product assessment against JP2023500935:
| Risk driver |
Claim element likely involved |
How competitors avoid |
| Product-level infringement |
Pharmaceutical composition definition |
Use different API form or different release/formulation |
| Structure-level infringement |
Formula/substituent limitations |
Change substituent set or omit required moiety |
| Method-level infringement |
Indication and dosing regimen |
Change route, regimen, or non-claimed indication |
| Follow-on coverage gaps |
Dependent narrowing details |
Use embodiments outside dependent limitations |
Key Takeaways
- JP2023500935’s enforceable scope is determined by its independent claims, typically anchored to compound identity (formula), product definition (composition), and/or therapeutic use (method claims).
- Japan’s patent landscape around this type of PCT-derived JP publication usually includes multiple family members and follow-on filings, with formulation and regimen claims providing the most common extension pathway.
- For FTO and competitive strategy, the critical step is to extract limiting elements from the independent claims and then map dependent claims into design-around lanes. Composition claims create higher practical enforcement leverage than method-only claims.
FAQs
1) Does JP2023500935 protect a product, a method, or both?
It is typically one or more of: pharmaceutical composition, compound, and method-of-treatment/use, as determined by its independent claim set.
2) What claim language most affects design-around in Japan?
The most decisive limitations are usually chemical structure boundaries (variables/substitutions), salt/polymorph/formulation requirements, and indication/regimen constraints in method claims.
3) Are dependent claims usually important in Japan infringement analysis?
Yes. Even if independent claims cover a broad field, dependent claims often define practical commercial embodiments. Competitors target missing dependent limitations where independent claims remain arguable.
4) How do follow-on patents change the JP landscape?
They extend coverage beyond the primary compound by adding formulation improvements, salt/polymorph variations, and dosing/combination regimens.
5) How should investors judge commercial impact from a JP publication like JP2023500935?
Focus on whether the family includes granted in-force members with composition-type independent claims and whether the dependent claims align with expected marketed formulations and regimens.
References
[1] Japan Patent Office. JP publication format and international application publication entry conventions (JP “2023/50xxxx” style). JPO official documentation and publication guidance.
[2] WIPO. PCT publication and international application family conventions for national/regional phases into Japan. World Intellectual Property Organization.
[3] INPADOC / EPO Patent Register. Family and legal status aggregation for JP national phase publications derived from PCT filings. EPO (INPADOC) database documentation.
